ARQ-197 (Tivantinib), a non-ATP-competitive c-Met inhibitor, induced apoptosis by >50% in 12 human myeloma cell lines, including those resistant to standard chemotherapy, and in a murine xenograft model of MM it was shown to reduce a subcutaneous tumour [30]. The gene discussed is MET; the disease is plasma cell myeloma.